JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcic, B. M.
Right arrow Articles by Erdös, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcic, B. M.
Right arrow Articles by Erdös, E. G.

Vol. 294, Issue 2, 605-612, August 2000

Protein Kinase C and Phosphatase Inhibitors Block the Ability of Angiotensin I-Converting Enzyme Inhibitors to Resensitize the Receptor to Bradykinin without Altering the Primary Effects of Bradykinin1

Branislav M. Marcic and Ervin G. Erdös

Departments of Pharmacology (B.M.M., E.G.E.) and Anesthesiology (E.G.E.), University of Illinois College of Medicine at Chicago, Chicago, Illinois

Angiotensin I-converting enzyme (kininase II) inhibitors (ACEis) are very widely used to treat cardiac conditions and nephropathies, but some of their beneficial activities cannot be attributed to enzyme inhibition alone. We investigated the effects of ACEis on the human bradykinin (BK) B2 receptor expressed in Chinese hamster ovary cells transfected with the cDNA of human receptor and ACE, and on human pulmonary endothelial cells that constitutively express both proteins. BK and its ACE-resistant peptide analog activated the B2 receptor to release arachidonic acid and elevate [Ca2+]i and subsequently desensitized it. The release of arachidonic by BK was independent of extracellular Ca2+. BK enhanced phosphorylation of the immunoprecipitated B2 receptor but enalaprilat significantly reduced it. ACEi resensitized the receptor by initiating a cross talk between the receptor and ACE. Protein kinase C and phosphatase inhibitors distinguished the signaling by the receptor when activated first by BK from BK acting on the resensitized receptor. Treatment of cells with 1 µM calphostin, 100 nM staurosporine, 100 nM calyculin, or 500 nM okadaic acid did not affect either one of the primary actions of BK on the receptor. Protein kinase C or phosphatase inhibitors, however, blocked the effects of BK on the receptor resensitized by enalaprilat or ramiprilat. The experiments clearly differentiate the primary activation of the receptor by BK from activation of the resensitized receptor after ACEi treatment. The existence of an intermediate component involved in the action of ACEis to enhance release of vasoactive mediators by BK is suggested.

1 This study was supported in part by National Institutes of Health National Heart, Lung and Blood Institute Grants HL36473 and HL58118.

0022-3565/00/2942-0605$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 FASEB J.Home page
Z. Chen, P. A. Deddish, R. D. Minshall, R. P. Becker, E. G. Erdos, and F. Tan
Human ACE and bradykinin B2 receptors form a complex at the plasma membrane
FASEB J, November 1, 2006; 20(13): 2261 - 2270.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
I. Fleming
Signaling by the Angiotensin-Converting Enzyme
Circ. Res., April 14, 2006; 98(7): 887 - 896.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Hecquet, D. Biyashev, F. Tan, and E. G. Erdos
Positive cooperativity between the thrombin and bradykinin B2 receptors enhances arachidonic acid release
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H948 - H958.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. Biyashev, F. Tan, Z. Chen, K. Zhang, P. A. Deddish, E. G. Erdos, and C. Hecquet
Kallikrein activates bradykinin B2 receptors in absence of kininogen
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1244 - H1250.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. J. Campbell, H. Krum, and M. D. Esler
Losartan Increases Bradykinin Levels in Hypertensive Humans
Circulation, January 25, 2005; 111(3): 315 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
E. G Erdos
Kinins, the long march--A personal view
Cardiovasc Res, June 1, 2002; 54(3): 485 - 491.
[Full Text] [PDF]

Home page
 HypertensionHome page
H. L. Jackman, M. G. Massad, M. Sekosan, F. Tan, V. Brovkovych, B. M. Marcic, and E. G. Erdos
Angiotensin 1-9 and 1-7 Release in Human Heart: Role of Cathepsin A
Hypertension, May 1, 2002; 39(5): 976 - 981.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
P. A. Deddish, B. M. Marcic, F. Tan, H. L. Jackman, Z. Chen, and E. G. Erdos
Neprilysin Inhibitors Potentiate Effects of Bradykinin on B2 Receptor
Hypertension, February 1, 2002; 39(2): 619 - 623.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.